Index

Page numbers in bold refer to tables. Page numbers in italic refer to figures.

AA amyloidosis, 300
abciximab, 134, 178
abdominal aortic aneurysm, 162
ablation of bone marrow, see high-dose chemo-radiation therapy
ABO blood types
  incompatible transfusions, 337–8
  maternal alloimmunization, 314
  neonates, RBC immunology, 309
  pretransfusion testing, 323–5
  von Willebrand factor levels, 121
absolute numbers of white cells, 184, 185
absorption
  folate, 51–2
  iron, 37
  vitamin B₁₂, 47
ABVD regimen, 274, 275
acanthocytes (spur cells), 33, 374
acid citrate dextrose (ACD), 137–8, 332, 333
acidosis, oxyhemoglobin dissociation curve, 19
acquired amegakaryocytic thrombocytopenia, 159
acquired bleeding disorders, 131–9
acquired hemolytic anemias, 75–90
acquired von Willebrand disease, 126–7, 137
essential thrombocytopenia, 223
acrocyanosis, 83
activated partial thromboplastin time, 94, 106, 133
hemophilia, 117
isolated prolonged, 107–8
monitoring anticoagulation, 109
neonates, 312
prothrombin time and, 108–9
activated protein C, 180
activated prothrombin complex concentrates, 119–20
acute bleeding, 24–5
hemophilia, treatment, 118–19
acute chest syndrome, 72
acute DIC, 161
acute GVHD, 356–8
acute hemolytic transfusion reactions, 326–7, 337–8
acute immune thrombocytopenia, 166, 167
acute leukemia, 235–50
acute lymphoblastic leukemia, 245–50, 383
allogeneic HCT, 249–50, 352
acute monocytic leukemia, 382
acute myelogenous leukemia (AML), 235–45, 382, 383
allogeneic HCT, 243, 352
acute myelogenous leukemia (AML), continued
myelodysplastic disorders and, 233, 245
with secondary myelodysplastic syndrome, 350
acute promyelocytic leukemia, 242, 244–5
ADAMTS13 (metalloprotease), 121, 163
additive solutions (AS), RBC products, 333
adenosine diphosphate (ADP)
platelet receptor disorders, 152
from platelets, 141
adenosine triphosphate (ATP), erythrocytes, 21
adhesion
neutrophils, 187
see also leukocyte adhesion deficiency platelets, 141
disorders, 142, 147–8
measurement, 147
adhesion molecules, see integrins
adipose cells, hematopoiesis, 13, 199
adjuvant therapies, hemophilia, 119
adrenal cortical insufficiency, anemia, 26
adult T-cell leukemia/lymphoma, 265
adventitial cells, bone marrow, 199
afibrinogenemia, 127, 129, 149, 150
agarose gel immunofixation, 289
age
bone marrow cellularity, 200
differential cell counts, 185
hemoglobin levels, 24
Hodgkin lymphoma, 268
agglutination, platelets, 173
agglutinins
hemolytic anemias, 29, 81
cold agglutinins, 81, 83
aggregation, platelets, 141, 142
disorders, 148–51
ristocetin-induced, 123, 148
studies, 147
aggressive non-Hodgkin lymphomas, 281–3
recurrent or refractory, hematopoietic cell transplantation, 285
aging, erythrocytes, 321
AL amyloidosis, 300–2
alcohol, Hodgkin lymphoma symptoms, 269
alcohol-induced thrombocytopenia, 159
alemtuzumab, chronic lymphocytic leukemia, 280
ALK gene, 264
allergy
eosinophilia, 194
transfusion reactions, 327–8, 337
alloantigens, 167
alloimmune blood donation, 319–20
alloimmune hematopoietic cell transplantation, 345, 346, 351–62
acute lymphoblastic leukemia, 249–50, 352
acute myelogenous leukemia, 243, 352
autologous HCT vs, 350
lymphomas, 283–5
myelodysplastic disorders, 232
outcomes, 361–2
primary myelofibrosis, 225
sickle cell disease, 73
alloimmune hemolytic anemia, 29
alloimmune neonatal neutropenia, 317
alloimmune thrombocytopenia, 167–8
neonatal, 167, 317–18
alloimmunization
HLA, RBC products, 342
maternal, 313–18
allopurinol, 241
all-trans retinoic acid, acute
promyelocytic leukemia, 244–5
alpha-1-antitrypsin, 100
alpha-1-antitrypsinPITTSBURGH, 110
alpha-2-antiplasmin, 97–8
deficiency, 110, 128–9
alpha2bbeta3integrin antagonists (glycoprotein IIb/IIIa inhibitors), 134, 178
α2 macroglobulin, neonates, 312
alpha-globin, 18, 19, 69–70
alpha granules, platelets, 140, 141
deficiency, 150–1
alpha-methyl dopa, 82
alpha thalassemias, 69–70
alternative complement pathway, atypical hemolytic uremic syndrome, 164, 165–6
altitude, 2,3-diphosphoglycerate, 20
alveolar hemorrhage, diffuse, 349
alveolar macrophages, 3
amegakaryocytic thrombocytopenia
acquired, 159
congenital, 145
amniocentesis
HDN, 315
hemophilia, 118
amyloid, 300
stains for, 213
amyloid β-protein precursor, 100
amyloidosis, 300–2
anaerobic glycolysis, 21
anagrelide, 222, 224
anamnestic response, transfusion reactions, 329
anaphylactic transfusion reactions, 327, 328, 337
anaphylactoid reactions, heparin, 171
anaplastic large cell lymphoma, 263–6
see genetics, 254
anaemia of chronic disease, 14, 25, 42
anemias, 24–34, 75
cytopenias, 14
2,3-diphosphoglycerate, 20
HDN, 314–15
laboratory diagnosis, 29–34
multiple myeloma, 293
physiologic, neonates, 309
signs and symptoms, 29, 40, 77
see also specific types
aneuploidy, 218
acute lymphoblastic leukemia, 247
angioimmunoblastic T-cell lymphoma, 265
angular cheilitis, 29, 40
anisocytosis, 31, 368, 372
anisopoikilocytosis, 31
ankyrin, 20
Ann Arbor staging system, 270
annexin V, 181
anthracyclines
acute myelogenous leukemia, 242
acute promyelocytic leukemia, 244
antibacterial agents
acute myelogenous leukemia, 241
hematopoietic cell transplantation, 361
MALT lymphoma, 278–9
neutropenia and, 189
antibodies
antiphospholipid antibody syndrome, 181
bound to erythrocytes, 324, 325
cytopenias, 14
factor VIII and factor IX, 119–20
fetal-maternal traffic, 313–18
folate deficiency, 53
hemolytic anemias, 78, 81
heparin-induced thrombocytopenia, 173
immune thrombocytopenia, 166
intrinsic factor, 49
screening, transfusion therapy, 323–5
transfusion-related acute lung injury, 339
see also autoantibodies; immunohistochemistry; inhibitors; monoclonal antibodies
anticoagulants (for blood components), 137–8, 320, 332
anticoagulants (for specimens), 5
APTT and PT, 108
EDTA-induced pseudothrombocytopenia, 173
anticoagulants (therapeutic)
APTT and PT, 108
monitoring, 109
bleeding, 135–6
plasma mixing test, 133
see also heparin; warfarin
anticoagulation systems, 98–100
anti-D immunoglobulin, 324, 336
antifibrin-generating agents, 178, 183
see also bivalirudin; heparin
antigens (alloantigens), 167
antihemophilic factor, 335–6
antihistamines, transfusion therapy, 337
anti-nuclear antibodies, 81
antithrombin, 99–100, 135
deficiency, 179, 180
neonates, 312
aortic aneurysm, 162
aortic stenosis, 132–3, 162–3
aorto-gonad mesonephros system, 2
apheresis, 320
aplastic anemia, 26
  allogeneic HCT, 352
apolipoprotein a, 175–6
apoptosis, 276
aprotinin, 335
arachidonic acid, 142
ara-G, prodrug (nelarabine), 249
argatroban, 136, 183
  monitoring levels, 109
arsenic trioxide, acute promyelocytic leukemia, 245
arterial thrombosis, 175–8
arthropathy, hemophilic, 115
artifacts, bone marrow touch imprints, 211
AS-1, AS-2, AS-3, AS-5 (additive solutions), RBC products, 333
ascites, bleeding disorder, 132
aspergillosis, hematopoietic cell transplantation, 360
aspirate clots, bone marrow, 209
aspiration, bone marrow, 200–5
aspirin, 134, 177
  essential thrombocytethmia, 223
  polycythemia vera, 221–2
atypical CML, BCR-ABL negative, 228
atypical hemolytic uremic syndrome, 164, 165–6
Auer rods, 240, 382, 383
autism spectrum disorders, folate deficiency, 53–4
autoactivation, coagulation proteins, 94, 101
autoantibodies
  cold, 29
  drug-induced hemolytic anemias, 84, 85
  folate deficiency, 53
  maternal, 318
  red cells, 324
  von Willebrand factor, 126
  warm, 28
autoimmune diseases
  autologous HCT, 346
  neutropenia, 190
  TTP, 163
  vitamin B₁₂ deficiency, 49
see also immune thrombocytopenia
autoimmune hemolytic anemias (AIHA), 28–9, 32, 81–2
  neonatal, 318
autologous blood, donation, 320
autologous hematopoietic cell transplantation, 345–51
  acute myelogenous leukemia, 243
  AL amyloidosis, 302
  lymphomas, 283–5
  aggressive NHL, 282
  multiple myeloma, 296
  autosomal hemophilia, 125
  autosplenectomy, 72
azacitidine, myelodysplastic disorders, 233
azurophilic granules, 187, 366
babesiosis, risk from transfusion, 343
back pain, multiple myeloma, 291
bacteria
  chronic granulomatous disease, 191–2
  hematopoietic cell transplantation, 360
  LAD-1, 192
  transfusion contamination, 328, 340
band 3 (erythrocyte protein), 20
  mutations, 65
  ‘bands’, 3, 364, 378
basophilic stippling, 18, 68, 370
basophils, 4, 7, 188, 366
  disorders, 195
B-cell lymphomas
  B lymphoblastic leukemia/lymphoma, 254–5
  mature, 256–63
see also diffuse large B-cell lymphoma
B cells, 5, 8
  development, 10
  flow cytometry, 253
BCNU regimen, bone marrow ablation, 284
BCR-ABL fusion gene, 222
  acute lymphoblastic leukemia, 247, 250
  chronic myeloid leukemia, 225, 240
  lymphoblastic lymphoma, 283
  T315I mutation, 227
BEACOPP regimen, Hodgkin lymphoma, 274
BEAM regimen, bone marrow ablation, 284
Bence Jones proteins, 292
Bernard–Soulier syndrome, 142, 146, 147–8
β₂ integrin, deficiency, 191–2
beta-globin, 18, 19
sickle cell disease, 71
thalassemia, 27
beta thalassemias, 70–1
hemoglobin S with, 72
Bethesda assay, 119
Bethesda units, 119
bilirubin, 36, 79
HDN, 316
Binet system, chronic lymphocytic leukemia, 280
biophysical profile score, fetus, 315–16
biopsy, bone marrow, 200–19
bisphosphonates, multiple myeloma, 296
bite cells, 33, 67
bivalirudin, 136, 178, 183
monitoring levels, 109
blast counts, hyperleukocytosis, 239
blast crisis, chronic myeloid leukemia, 226, 240
blastoid variant, mantle cell lymphoma, 259
bleeding, 24–5, 132
after bone marrow sampling, 202
gastrointestinal tract, aortic stenosis and, 132–3, 162–3
hemophilia, 114–16
treatment, 118–19
rare bleeding disorders, 127
thrombocytopenia, 154–5
von Willebrand disease, 121
bleeding disorders, 103–11
acquired, 131–9
congenital, 112–30
bleeding time, 106, 146–7
prolonged
normal platelet count and, 109
platelet defects and, 109–10
blood, 5
hematopoietic cells from, 344
whole (for transfusion), 332
blood cells, 6
see also specific types
blood components (for transfusion), 332–6
filtered and irradiated, acute myelogenous leukemia, 241
blood donation, 319–20
graft-versus-host disease, 355
blood loss
acute, 24–5
iron deficiency anemia, 39
blood smears, see peripheral blood smears
blood transfusion, see transfusion therapy
blood vessels
bone marrow, 199
injuries, clotting, 175
see also endothelial cells
blood volume, 5
B lymphoblastic leukemia/lymphoma, 254–5
Bombay erythrocyte phenotype, 192
bone, 197–8
bone marrow biopsy, 209
hemolytic facies, 308
multiple myeloma, 290, 291, 292
imaging, 295
pain, acute myelogenous leukemia, 240
bone marrow, 197–219
ablative treatment, see high-dose chemo-radiation therapy
diagnostic testing, 200–19
drug injury, 158
failure states, 15
see also aplastic anemia
harvesting, 347
hemolytic anemias, 81
infiltration, 26, 157
megaloblastosis, 59
microenvironments, 12–13
neutrophils, 3
paroxysmal nocturnal hemoglobinuria, 89
radiolabeled monoclonal antibodies on, 278
structure, 197–200
transplantation, see hematopoietic cell transplantation
bortezomib, multiple myeloma, 296
bovine thrombin, 137
bradykinin, 94
brain
  folate deficiency of, 53–4
  see also central nervous system
brodifacoum, 137
B symptoms, 263
  Hodgkin lymphoma vs NHL, 269
Burkitt lymphoma, 260–1, 282–3
genetics, 254
burr cells, 33
burst forming unit-erythroid colonies, 11
busulfan, cyto reduction, 359
C1 esterase inhibitor, 100
C3 complement, 78
C4b-binding protein, 98, 180
calcineurin inhibitors, 358
calcium
  chelation, 138
  platelets, 142, 143
cAMP, 141–3
Canadian Consensus Conference criteria,
  transfusion-related acute lung injury, 339
cancellous bone, 197
candidiasis, hematopoietic cell transplantation, 360
capillary blood samples, neonates,
  hemoglobin levels, 309
carboxylation, proenzymes, 93
cardiopulmonary bypass
  neutropenia, 190
  platelets, 134, 162
carriers, hemophilia, 114–15
catalase-positive bacteria, 193
CBV regimen, bone marrow ablation, 284
  ’CD’ (markers), 11
  bone marrow cells, 215
  hemolytic anemias, 81
  lymphocytes, 5
CD18, deficiency, 191–2
CD20, monoclonal antibodies, 276–7, 278
CD34+ cells, 347
CD40-ligand, transfusion-related acute lung injury, 339
celiac sprue, 54
cellularity, bone marrow, 200
cement lines, 197
central nervous system
  acute lymphoblastic leukemia, 247, 249
  acute myelogenous leukemia, 240
  Burkitt lymphoma, 260
  folate deficiency of, 53–4
  hemorrhage, 135, 317
  vitamin B12 deficiency, 55, 60
centroblasts, follicular lymphoma, 257–8
cerebral anticoagulants, 100
cerebral folate deficiency, 53–4
cerebral hemorrhage, 135
Chediak–Higashi syndrome, 150, 193
cel esion, calcium, 137, 138
chemokines, stored blood components, 322
chemotactic agents, 191
chemotherapy
  acute lymphoblastic leukemia, 248–50
  acute myelogenous leukemia
    causation, 236
    treatment, 242–4
cytopenia, 14
differential cell counts, 186
Hodgkin lymphoma, 272–5
  indolent non-Hodgkin lymphomas, 277
  myelodysplastic disorders,
    cytogenetics, 231
  see also high-dose chemo-radiation therapy
CHIC2 domain, deletion, 195
children, 307–18
  Burkitt lymphoma, 260
  cryoprecipitate, dosages, 335
  folate deficiency, 53
  immune thrombocytopenia, 166
  iron deficiency anemia, 39, 40
  see also acute lymphoblastic leukemia
chloromas, extramedullary, 239
CHOP regimen, aggressive NHL, 281–2
chorionic villus sampling, hemophilia, 118
chromosomes, 218–19
  acute lymphoblastic leukemia, 247
  isochromosome 7q, 265
  lymphomas, 253–4
  myelodysplastic disorders, 231
  X chromosome lyonization, 114–15
chronic disease, anemia of, 14, 25, 42
chronic disseminated intravascular coagulation, 138–9, 161–2
chronic eosinophilic leukemia, not otherwise specified, 222
chronic granulomatous disease, 191–2
chronic GVHD, 356, 359
chronic immune thrombocytopenia, 166–7
chronic lymphocytic leukemia/small lymphoblastic lymphoma, 256, 257, 276, 279–81, 380
immunophenotyping, 253
chronic myeloid leukemia, 222, 225–7, 381
acute myelogenous leukemia vs, 240
chronic myelomonocytic leukemia, 228
chronic neutrophilic leukemia, 222
CHS1 gene, 193
circulatory overload, 328, 338–9
cirrhosis of liver, 138
citrate phosphate dextrose (CPD), 332
RBC products, shelf life, 333
c-KIT mutations, mastocytosis, 222
classical Hodgkin lymphoma, 266–7, 271–2
clerical errors, transfusion reactions, 326, 337–8
clofarabine, 249
clopidogrel, 134, 177
clots
bone marrow aspirates, 210
euglobulin lysis time, 129
lysis (thrombolytic therapy), 182
red vs white, 175
see also thrombosis
clotting times, 106, 107, 108
cramping, platelets, 172–3
c-Mpl (TPO receptor), 143, 145, 158
CMV (cytomegalovirus), 14
blood products, 342
c-Myc protein, Burkitt lymphoma, 260
coaugulation cascade hypothesis, 104–5
coaugulation factor inhibitors, 136
coaugulation protein system, 92–7
autoactivation, 94
defects, 103–4, 132, 135–8
plasma transfusion for, 334
pediatrics, 311–12
stored blood components, 321
see also extrinsic coagulation system; intrinsic coagulation system
cobalamin, see vitamin B₁₂
CODOX-M/IVAC regimen, Burkitt lymphoma, 282–3
cold agglutinin disease, 82–3, 373
cold agglutinins, 81, 83
cold autoantibodies, 29
collagen, stains for, 213
collagen binding assay, von Willebrand factor, 123
colony-forming unit assay, 347
comitant veins, 199
common lymphoid progenitor cells, 10
common myeloid progenitor cells, 9
common pathway, coagulation cascade hypothesis, 105
compartment syndrome, 115
complement system
activation products, testing, 325
atypical hemolytic uremic syndrome, 164, 165–6
C3 complement, 78
complete blood count (CBC), 29, 30, 32, 40
hemolytic anemias, 77
vitamin B₁₂/folate deficiency, 56
conditioning, see high-dose chemoradiation therapy
congenital amegakaryocytic thrombocytopenia, 145
congenital bleeding disorders, 112–30
congenital heart disease
thrombocytopenia, 162
von Willebrand factor, 126
congenital hematopoietic disorders, allogeneic HCT, 352
congenital hemolytic anemias, 62–74
congenital hypoplastic anemia, 26
congenital neutropenia (severe), 190
congenital non-spherocytic hemolytic anemias, 21, 68
Congor red stain, 213
conjugated bilirubin, 79
consent, bone marrow sampling, 202
consolidation therapy
acute lymphoblastic leukemia, 249
acute myelogenous leukemia, 242, 243
consumptive disorders
platelets, 161–6
see also specific disorders
contact system (kallikrein/kinin system), 93–4, 97, 112
contraceptives
factor V Leiden and, 179
venous thrombosis risk, 182
Cooley’s anemia, 70–1, 369
Coombs test, 14, 78, 79, 324, 325
see also indirect antiglobulin test
cooperaitivity, hemoglobin, 19
cord blood, see umbilical cord blood
core binding factor leukemias, 236
core biopsy, bone marrow, 204, 208–10
corrected reticulocyte count, 31
cortical bone, 197
corticosteroid therapy
differential cell counts, 186
GVHD prevention and treatment, 358
coumadin skin necrosis, 180
cow’s milk
folate deficiency, 53
iron deficiency anemia, 39
CRAB mnemonic, multiple myeloma, 291
Creutzfeldt–Jakob disease (variant), risk from transfusion, 343
crossmatching
HLA system, 353
transfusion therapy, 324, 325
cryoprecipitate, 335–6
cryopreservation, 347–8
cubam receptors, 47
cultures, hematopoietic stem cells, 11–12
cutaneous mastocytosis, 227
cyanocobalamin, 60
cyclic neutropenia, 190
cyclic nucleotides, see cAMP
cyclooxygenase, 142
cyclophosphamide, cytoreduction, 359
cyclosporine, 358
cystathionine β-synthase, deficiency, 176
cytarabine, acute myelogenous leukemia, 242, 243, 244
cytogenetics, 218–19
acute lymphoblastic leukemia, 246–7, 248
acute myelogenous leukemia, 238, 239
CLL/SLL, 256
multiple myeloma, 293
myelodysplastic disorders, 231
myeloproliferative neoplasms, 222
see also genetics
cytokines, 11
for cytopenias, 14–15
graft-versus-host disease, 357
hematopoiesis, 13
multiple myeloma, 292
POEMS syndrome, 302
stored blood components, 321–2
cytomegalovirus (CMV), 14
blood products, 342
cytopenias, 14–15
see also specific conditions
cytoreduction, 359
cytosis (suffix), 185
cytotoxic T cells, 8
dabigatran, 136
dacrocytes (tear-drop cells), 157, 376
dasatinib
acute lymphoblastic leukemia, 250
chronic myeloid leukemia, 226, 227
daunorubicin
acute myelogenous leukemia, 242
acute promyelocytic leukemia, 244
DDAVP, see desmopressin
D-dimer, 97, 138
dead fetus syndrome, 162
decay accelerating factor, 28
deep vein thrombosis, 178–83
venous limb gangrene, 162, 172
defibrotide, 361
degrannulation, mast cells, 227
delayed-onset HIT, 171
delayed reactions, transfusion, 328–9, 338
δ-storage pool deficiency, 150–1
dendritic cells, 7–8
dense granules, platelets, 140, 141
disorders, 150–1
Glanzmann thrombasthenia, 150
secretion measurement, 147
deoxyadenosylcobalamin, 48
desmopressin
hemophilia, 119
platelet function defects, 152–3
von Willebrand disease, 125, 126
developing countries, vitamin $B_{12}$
deficiency, 54–5
diacylglycerol, 141–3
Diamond–Blackfan anemia, 26
diapedesis, 186
diets
folate, 45–7
iron, 37
vitamin $B_{12}$, 44–5
see also vegetarian diets
differential cell counts
blood, 184, 185, 186
bone marrow, 206–7
differentiation
impairment, acute myelogenous leukemia, 235, 236
diffuse alveolar hemorrhage, 349
diffuse large B-cell lymphoma, 261–3, 272, 386
diffuse large B-cell lymphoma, not otherwise specified, 262
DiGeorge syndrome, 145
dilute APTT, 108
dilute Russell viper venom time, 108
dilutional coagulopathy, 137
dimethyl sulfoxide, 347–8
2,3-diphosphoglycerate, 19, 20
deficiency, 22
loss from stored blood components, 321
*Diphyllolothrium latum*, 49
direct antiglobulin test, see Coombs test
directed blood donation, 319–20
graft-versus-host disease, 355
direct thrombin inhibitors, 136, 183
see also argatroban; bivalirudin
disseminated intravascular coagulation, 28, 138–9, 161–2, 241
acute promyelocytic leukemia, 244
protein C deficiency, 180
dissociation curve, oxyhemoglobin, 19–20
DNA
immunoglobulins, 10
megakaryocytes, 9
megaloblastic anemia, 44
Döhle bodies, 144, 145, 378
Donath–Landeinster antibody test, 81, 84
donation of blood, 319–20
graft-versus-host disease, 355
donor leukocyte infusion, 354
donors
blood, 319–20
hematopoietic cell transplantation, 354
dose-response curves, tumors, 345–6
dot plots, flow cytometry, 216
drug-induced immune thrombocytopenic purpura, 168, 169, 170
drugs
antiplatelet drugs, 133, 134, 177–8
bone marrow injury, 158
cytopenias, 14
eosinophilia, 194
erthrodysplasia, 231
folate deficiency, 51, 54
immune-mediated hemolytic anemias, 84–6
immune thrombocytopenia, 167
neutropenia caused by, 190
thrombotic thrombocytopenic purpura, 163–5
vitamin $B_{12}$ deficiency, 50
warm antibody AIHA, 82
‘dry tap’, 204, 211
Durie Salmon Staging System, multiple myeloma, 294
dysfibrinogenemia, 108, 127, 129, 179, 180
dysplasminogenemia, 181
dysprothrombinemia, 129
Eastern Cooperative Oncology Group scale, 271
echymosis, 132, 155
echinocytes, 33
EDTA-induced pseudothrombocytopenia, 173
elderly persons
decreases, acute myelogenous leukemia, treatment, 243–4
autologous HCT, 283
hemoglobin levels, 24
venous thrombosis risk, 181
electrocardiography, AL amyloidosis, 302
electrophoresis
M-spike, 289, 294
see also gel electrophoresis
eosinocytes, 63, 66
eosinocytosis, hereditary, 63, 65
etrombopag, 15, 167
Embden–Meyerhof pathway, 21
embryo, hematopoiesis, 307–8
emergency transfusion, 325
endemic Burkitt lymphoma, 261
endocrine anemias, 26
endothelial cells
antiphospholipid antibody syndrome, 181
hyperhomocysteinemia, 176–7
origins, 2
thrombosis and, 92, 100
endotoxin, graft-versus-host disease, 357
engraftment, HCT, 349–50, 354
enzyme defects, anemias, 28, 65–8
enzyme immunoassay, heparin-induced thrombocytopenia and, 172
eosinopenia, 194
eosinophilia, 194
neoplasms with PDGFRx or FGFR1 abnormalities, 227–8
see also chronic eosinophilic leukemia, not otherwise specified
eosinophils, 4, 7, 188, 366
bone marrow biopsy, 210
counts, 188
pediatric, 311
disorders, 194–5
epsilon aminocaproic acid, 129
Epstein–Barr virus, Burkitt lymphoma, 261
eptifibatide, 134, 178
erthroblastosis fetalis (hemolytic disease of the newborn), 314–16, 336
erythrocytes (RBC), 2–3, 7, 16–23, 31–2, 33, 363
antibodies vs, 14, 324, 325
aplasia, 26
basophilic stippling, 18, 68, 370
blood storage, 321
Bombay phenotype, 192
counts, 25
pediatric, 310
distribution width (RDW), 30
fetus, 307, 313
hemolytic anemias, 63
hypochromic, 31, 32, 41, 367, 368, 369
iron release, 36
membranes, see membranes, erythrocytes
myelodysplastic disorders, 231
neonates, 309
nucleated, 313
premature destruction, 27–9
rouleaux, 384
transfusions, 332–3
acute myelogenous leukemia, 241
febrile reactions, 337
folate/vitamin B12 deficiency, 59
HCT recovery, 349
hemolysis, 88, 90
septicemia, 340
erythromelalgia, 220
erthropoiesis, 2–3, 9, 17–18
bone marrow capacity, 75
fetus, 8
erythropoietin (EPO), 13, 14–15, 16–17, 25–6
myelodysplastic disorders, 233
for renal failure, 134
Escherichia coli, hemolytic uremic syndrome, 165
esophagus, webs, 40
essential thrombocythemia (ET), 222, 223–4, 381
ethnicity
monoclonal gammopathy of undetermined significance, 296–7
multiple myeloma, 291
rare bleeding disorders, 127
ethylenediaminetetraacetic acid, pseudothrombocytopenia, 173
euglobulin clot lysis time, 129
examination (physical), bleeding disorders, 132–3
exchange transfusion
HDN, 316
of RBCs, 333
sickle cell disease, 73
extramedullary chloromas, 239
extramedullary hematopoiesis, 2, 29, 308
extranodal NK/T-cell lymphoma, nasal type, 265
extravascular hemolysis, 77
from transfusion therapy, 328–9
extrinsic coagulation system, 105
screening tests and, 107
FAB classification, acute myelogenous leukemia, 236, 237
facial bones, hemolytic facies, 308
factor II, see prothrombin
factor V, 92, 94, 95, 96
deficiency, 129
inhibitors, 136–7
neonates, 312
screening tests and, 106, 107
stored blood components, 321, 334
factor V Leiden, 178–9
factor VII, 93, 95, 96, 101
deficiency, 108, 127
neonates, 312
stored blood components, 321, 334
factor VIIa, 92, 97, 100, 101
recombinant, 119, 120, 153
screening tests and, 107
factor VIII, 94, 95, 96
assay, 123
deficiency, 107, 112–20
inhibitors, 119–20, 136, 137
neonates, 312
replacement therapy, 118–19
stored blood components, 321, 334
von Willebrand factor and, 121
factor VIIIa, 113
factor IX, 92, 93, 95, 96, 100, 101
deficiency, 107, 112–20
inhibitors, 119–20
neonates, 312
replacement therapy, 118–19
screening tests and, 106
factor IXa, 92, 97, 113
factor X, 93, 95, 96, 113
deficiency, 129
neonates, 312
screening tests and, 106, 107
factor Xa, 97, 100
factor XI, 96
deficiency, 107, 127
screening tests and, 106
factor XII, 93, 94, 101
deficiency, 107
screening tests and, 106
stored blood components, 321
factor XIIa, 101
factor XIII, 94, 96, 97
deficiency, 110, 127, 128, 129
familial amyloid polyneuropathy, 300
fat cells (adipose cells), hematopoiesis, 13, 199
febrile nonhemolytic transfusion reactions, 327, 336–7
ferritin, 36, 38
folate deficiency, 53
hematopoiesis, 8, 19, 308
hydrops fetalis, 70
fetal hemoglobin, 8, 19
hemoglobins, 8, 19, 308–9
fertility consultation, acute myelogenous leukemia, 241
fetal-to-maternal hemorrhage, 313–14
fetomaternal cell traffic, 313–14
see also transplacental transfer
fetomaternal unit, disorders, 313–18
fever
bleeding disorder, 132
transfusion reactions, 326, 327
fibrin clots, 175
fibrinogen, 94, 96
apolipoprotein a on, 176
deficiency, 128
fibrinogen, continued
disorders, 108, 149, 150
neonates, 312
platelet aggregation, 141, 142
replacement therapy, 335–6
screening tests and, 106, 107
fibrinolytic system, 97–8
deficiencies of inhibitors, 128–9
liver disease, 138
fibrin sealant, 335
fibroblasts, 13
filgrastim, HCT recovery, 349
FIPL1-PDGFRA mutation, 228
FISH, see fluorescent in-situ hybridization
Fitzgerald factor, see high molecular weight kininogen
5 M urea clot solubility assay, 128
FK-506 (tacrolimus), GVHD prevention, 358
Fletcher factor, see prekallikrein
flow cytometry
acute myelogenous leukemia, 238
bone marrow, 214–18
immunophenotyping, lymphomas, 253
peripheral blood, 81
‘flower cells’, 265
fludarabine, chronic lymphocytic leukemia, 280
fluorescent in-situ hybridization (FISH), 218
CLL/SLL, 256
lymphomas, 254
folate
deficiency, 26, 44–61
dosages, 60
levels, 57
folinic acid, 52
follicular lymphoma, 257–8, 385, 386
genetics, 254
immunophenotyping, 253
fondaparinux, 135, 136, 178
5-formyl-THF (folinic acid), 52
fortification of foods, vitamin B12 and folate, 46
fragmentation hemolysis, 86
free light chain assay, 289–90
French-American-British classification, acute myelogenous leukemia, 236, 237
fresh frozen plasma, 128, 138, 333–4
fungal infections, hematopoietic cell transplantation, 360
fusion genes
hypereosinophilic syndrome, 195
see also BCR-ABL fusion gene
gain of function mutations, VWF gene, 125
gallstones, 29, 64
Ga1, Gaq, Gas (GTP-binding proteins), 143
gamma-globin, 18, 19
gastrectomy, vitamin B12 deficiency, 49
gastric bypass surgery, iron deficiency anemia, 38–9
gastrinoma, vitamin B12 deficiency, 49
gastrointestinal tract
bleeding, aortic stenosis and, 132–3, 162–3
HCT complications, 360
iron deficiency anemia, 38–9
MALT lymphoma, 259, 278–9
GATA-1 mutation X-linked macrothrombocytopenia with dyserthropoiesis, 146
gelatinase granules, 187–8
gel electrophoresis
alpha thalassemias, 70
beta thalassemias, 71
genetics
hemophilia, 113–14
testing, 117
lymphomas, 253–4
von Willebrand disease, 121
see also cytogenetics
germinai centers, lymph nodes, 8
giant platelets, 144, 173
Glanzmann thrombasthenia, 149–50
globin chains, 18–19
synthesis assays, 70
thalassemias, 27, 69
glossitis, 40, 55
Glücksberg grading, graft-versus-host disease, 357–8
glucose-6-phosphate dehydrogenase, 28
deficiency, 66–7
variants, 67
glutathione, 23, 67
glycocalyx, platelets, 140
glycolysis, 21–2
glycoprotein Ib, platelet adhesion, 142
glycoprotein Ib–IX–V Bernard–Soulier syndrome, 142, 146, 147–8
inhibitors, platelet adhesion, 141
glycoprotein IIb/IIIa, 141, 142, 143
disorders, 148–50
inhibitors, 134, 178
glycoprotein VI, 141
glycosylphosphatidylinositol-linked proteins, 81, 89
gonadotrophin agonists, 241
G-proteins, activation defects, 152
graft-versus-host disease, 355–9, 361
transfusion-associated, 341
graft-versus-leukemia effect, 243, 354
graft-versus-tumor effect, 346, 352
granules
azurophilic, 187, 366
eosinophils, 188
neutrophils, 187–8
deficiency, 193
platelets, see alpha granules; dense granules
siderotic, 212
toxic granulation, 378
granulocyte colony-stimulating factor (G-CSF), 15
for alloimmune neonatal neutropenia, 317
HCT recovery, 349, 359
hematopoiesis, 13
stem cell cultures, 11
granulocyte-macrophage colony-stimulating factor (GM-CSF)
hematopoiesis, 13
stem cell cultures, 11
granulocytes, 2, 7, 9
arrangement in marrow, 199
leukoerythroblastosis, 157
myeloid/erythroid ratio, 207
products for transfusion, 336
progenitor cells, 210
reduction, 14
granulocytic sarcomas, 239
granulocytopenia, 14
gray platelet syndrome, 145, 150–1
Grocott’s methenamine silver stain, 213
growth factors
hematopoiesis, 13, 16
macrophage colony-stimulating factor, 13
stem cell cultures, 11
VEGF, POEMS syndrome, 302
see also granulocyte colony-stimulating factor
GTP-binding proteins, platelets, 142, 143
Hageman factor, see factor XII
half-life
platelets, 143
reduction, 166–72
see also life spans
‘hallmark’ cells, 264
Ham’s test, 89
H antigen, nonfucosylated, 192
haplotypes, MHC, 353
haptens, 84, 85
haptocorrin, 47
haptoglobin, 80
harvesting, autologous hematopoietic cells, 346–7
HCT, see hematopoietic cell transplantation
HDN, see hemolytic disease of the newborn
health care staff, see personnel
heart
AL amyloidosis, 302
see also congenital heart disease; valvular heart disease
heavy chains, translocations, multiple
myeloma, 293
Heinz bodies, 67
HELLP syndrome, 165, 313
helmet cells, 79, 372
hemarthrosis, 115
hematoblasts, 2
hematocrit, 5, 24, 25
  blood donors, 320
erthropoietin levels vs, 17
  neonates, 309, 312
  pediatric, 310
hematology, 1–5
hematopoiesis, 6–15
  adipose cells, 13, 199
  assays, 11–12
  bone marrow biopsy, 211
  development of, 8, 307–8
  myeloid cells, 186–7
  neonates, 309
  regulation, 13
hematopoietic cells, arrangement in marrow, 199–200, 209–10
hematopoietic cell transplantation, 344–62
  alloimmune thrombocytopenia after, 168
  lymphomas, 283–5
  primary myelofibrosis, 225
  TTP after, 163–5
  see also allogeneic hematopoietic cell transplantation; autologous hematopoietic cell transplantation
hematopoietic stem cells (HSC), 1, 10–12
  mutations, 15
  origins, 2–5
hematopoietic system, defined, 6
heme proteins, 35
  dietary, 37
hemoanalysis, neutropenia, 190
hemodilution, 156, 159
hemoglobin(s), 2, 7, 18–20
  fetus, 8, 19, 308–9
  free, 78, 80–1
  iron content, 35
  levels, 24, 25
  neonates, 309
  pediatric, 310
  transfusion triggers, 333
newborn, 309
  unstable, 73–4
hemoglobin A, 8, 19
hemoglobin A2, 19
hemoglobin Barts, 69, 70
hemoglobin F (fetal hemoglobin), 8, 19, 308
hemoglobin H disease, 69–70
hemoglobinopathies, 19, 27, 68–73, 352
hemoglobin S, 27, 71
hemoglobinuria
  paroxysmal cold, 83–4
  paroxysmal nocturnal, 28, 89–90
hemolysis, 18, 75–81
  intravascular, 71–2, 77, 329
hemolytic anemias, 27–9, 371
  acquired, 75–90
  alloimmune, 29
  autoimmune (AIHA), 28–9, 32, 81–2
  neonatal, 318
  congenital, 62–74
  congenital non-spherocytic, 21, 68
  immune-mediated, 81–6
  microangiopathic, 28, 372
  fetus, 313
  see also fragmentation hemolysis; thrombotic microangiopathy
  neonatal autoimmune, 318
hemolytic disease of the newborn (HDN), 314–16, 336
hemolytic facies, 308
hemolytic transfusion reactions
  acute, 326–7, 337–8
  delayed, 328–9, 338
hemolytic uremic syndrome, 28, 165–6
hemophilia, 112–20
  treatment centers, 120
hemophiloid states, 104
hemorrhage, see bleeding
hemosiderin, 36, 212
  urine, 80
hemostasis, 91–102
  pediatrics, 311–12
heparin, 99, 135–6, 178, 183
  monitoring levels, 109
heparin cofactor II, 100
heparin-induced thrombocytopenia, 136, 154, 161, 168–72
  drug-induced immune
  thrombocytopenic purpura vs, 170
heparin type anticoagulants, 135–6, 183
hepatic period, hematopoiesis, 307, 308
hepatitis B, risk from transfusion, 342
hepatitis C
  bleeding disorder, 138
  risk from transfusion, 342
hepatomegaly, bleeding disorder, 132
hepatosplenic T-cell lymphoma, 265
genetics, 254
hepcidin, 14, 25, 42
hereditary elliptocytosis, 63, 65
hereditary folate malabsorption, 54
hereditary myeloperoxidase syndrome, 194
hereditary spherocytosis, 27, 63–5
hereditary systemic amyloidosis, 300
Hermansky–Pudlak syndrome, 150
herpes simplex, HCT recovery, 349
heterozygosity, glucose-6-phosphate dehydrogenase deficiency, 67
hexose monophosphate shunt, 22, 23
enzyme defect, 28
Heyde’s syndrome, 132–3, 162–3
high-dose chemo-radiation therapy, 243, 346, 348, 359
  AL amyloidosis, 302
  Hodgkin lymphoma, 284
  multiple myeloma, 296
  reduced intensity conditioning, 243, 351
high-dose cytarabine, acute myelogenous leukemia, 243
high molecular weight kininogen, 94–5
deficiency, 107
screening tests and, 106
high-performance liquid chromatography (HPLC)
  alpha thalassemias, 70
  beta thalassemias, 71
histochemical stains, see stains
history-taking
  bleeding disorders, 131–2
  lymphomas, 270–1
HIV infection, 14
  risk from transfusion therapy, 342
HLA alloimmunization, RBC products, 342
HLA system, 353–4
Hodgkin lymphoma, 266–7
classification, 271–2
  hematopoietic cell transplantation, 283–4
  non-Hodgkin lymphomas vs, 268–72
  Reed–Sternberg cells, 267, 387
treatment, 272–5, 285
homeostasis, hematopoietic, 6–7
homocysteine, 52, 176
  hyperhomocysteinemia, 55–6, 176–7, 179
levels, 57–9
hormone suppression therapy, von Willebrand disease, 126
Howell–Jolly bodies, 72, 370
Howship’s lacunae, 198
HPA-1a antigen system, neonatal alloimmune thrombocytopenia, 317
human immunodeficiency virus, see HIV infection
human leukocyte antigen system (HLA system), 353–4
human T-cell lymphotropic virus, risk from transfusion, 342
hydration, acute myelogenous leukemia, 241
hydrogen peroxide, 23, 193
hydrops fetalis, 69, 70, 315
hydroxycarbamide, 8
hydroxyurea, 73
  acute myelogenous leukemia, 241, 244
  essential thrombocythemia, 223
hyperbilirubinemia, HDN, 316
hypercalcemia, multiple myeloma, 291, 292–3
hyper-CVAD regimen, aggressive NHL, 282
hyperdiploidy, 218
  acute lymphoblastic leukemia, 246, 247
  multiple myeloma, 293
  precursor lymphoid neoplasms, 255
hypereosinophilic syndrome (idiopathic), 195
hyperhemolytic transfusion reactions, 338
hyperhomocysteinemia, 55–6, 176–7, 179
hyperleukocytosis, 239, 245, 247
hyperreactive von Willebrand factor, 125
hypersegmentation, neutrophils, 56, 57, 60
hypersplenism, 86–7, 132, 159–61
hyperviscosity syndrome, 291
hypochlorous acid, 194
hypochromic erythrocytes, 31, 32, 41, 367, 368, 369
hypodiploidy, 218
  acute lymphoblastic leukemia, 246, 247
  precursor lymphoid neoplasms, 255
hypofibrinogenemia, 108, 129
hypomethylating agents,
  myelodysplastic disorders, 233
hypotension, 132
hypothermia, 161
hypothyroidism
  anemia, 26
  von Willebrand factor, 126
hypoxia, 2,3-diphosphoglycerate, 20
IBMTR grading, graft-versus-host
disease, 357–8
idarubicin, acute myelogenous leukemia,
  242
identification of patient, transfusion
therapy, 323, 325
idiopathic hypereosinophilic syndrome,
  195
idiopathic immune-mediated
  thrombocytopenia, 14
idiopathic pneumonia syndrome, 349
idiopathic thrombotic thrombocytopenic
purpura, 163
IgA, anaphylactic transfusion reactions,
  327, 337
IgE receptors, eosinophils, 188
IgG
  hemolytic anemias, 78, 79
  heparin-induced thrombocytopenia,
  170
  maternal, 313, 314
IgM, cold agglutinin disease, 82–3, 373
Ii antigen system, neonates, 309
imatinib
  acute lymphoblastic leukemia, 250
  chronic myeloid leukemia, 226–7
  hypereosinophilic syndrome, 195
  immune complexes, drug-induced
  hemolytic anemias, 84, 85
immune-mediated hemolytic anemias,
  81–6
immune thrombocytopenia, 14, 166–7
  drug-induced, 168, 169, 170
  see also alloimmune thrombocytopenia
immune tolerance induction regimens,
  120
immunodeficiency-associated Burkitt
  lymphoma, 261
immunodeficient mice (non-obese
  SCID mice), transplantation
  assays, 12
immunofixation, agarose gel, 289
immunogenic drug-RBC complex
  mechanism, hemolytic anemias,
  84–6
immunoglobulins, 10
  anti-D, 324, 336
HDN, 314
  monoclonal, 134, 137, 287–90
  see also plasma cells, disorders
immunohistochemistry, 214–16
  acute myelogenous leukemia, 240
  lymphomas, 253
immunologic reconstitution, HCT, 355,
  361
immunomodulation, transfusion-related,
  341–2
immunophenotyping
  acute lymphoblastic leukemia, 249
  acute myelogenous leukemia, 236–8
  flow cytometry, lymphomas, 253
immunosuppressive therapy, 232, 358,
  359
immunotherapy, see rituximab
indirect antiglobulin test, 78, 79
indolent non-Hodgkin lymphomas,
  275–9
hematopoietic cell transplantation,
  284–5
induction therapy
  acute lymphoblastic leukemia, 249
  acute myelogenous leukemia, 242
infections
  bone marrow infiltration, 157
  bone marrow stains for, 214
  chronic granulomatous disease,
  192–3
  consumptive thrombocytopenia, 162
  cytopenias, 14, 189, 190
differential cell counts, 186

disseminated intravascular coagulation, 161, 162

HCT recovery, 349, 359–60

hemolysis, 28, 29, 87–8

hemolytic uremic syndrome, 165

lymph nodes, 269

myelodysplastic disorders, 229

neutropenia, 189, 190

sickle cell disease, 72

from transfusion therapy, 320, 342–3

see also bacteria; viral infections

inflammation, anemia of, 14, 25, 42

inhibitors (alloantibodies)

factor V, 136–7

factor VIII and factor IX, 119–20, 136, 137

plasma mixing test, 133

injuries

blood vessels, clotting, 175

ink dot nuclei, 210

inositol 1,4,5-triphosphate, 141–3

INR (International Normalized Ratio),

109, 135, 172

integrins, 13

neutrophil adhesion, 187, 191–2

interferon, indolent non-Hodgkin lymphomas, 278

interferon-α, essential thrombocythemia, 223–4

interleukins, stem cell cultures, 11

International Normalized Ratio (INR),

109, 135, 172

international prognostic scoring systems

aggressive non-Hodgkin lymphomas, 281

Hodgkin lymphoma, 273

myelodysplastic disorders, 231–2

International Staging System, multiple myeloma, 294

International Working Group score, primary myelofibrosis, 224

intracerebral hemorrhage, 135

intracranial hemorrhage, neonatal alloimmune thrombocytopenia, 317

intruterine growth retardation, 313

intruterine intravascular transfusion, 315–16

intravascular compartment, 1

intravascular hemolysis, 71–2, 77, 329

intravenous immunoglobulins

hematopoietic cell transplantation, 361

neonatal alloimmune thrombocytopenia, 317–18

see also Rh immunoglobulin therapy

intrinsic coagulation system, 104, 105, 112

screening tests and, 106

intrinsic factor, 26, 47, 49

antibodies, 49

serum levels, 59

inverted-Y field, radiation therapy, 273

involved-field radiotherapy, Hodgkin lymphoma, 273

iron, content of RBC products, 342

iron cycle, 36–7

iron deficiency anemia, 25, 32, 35–43, 367, 368

bone marrow assessment, 212

signs and symptoms, 29, 40

thrombocytopenia, 159

iron metabolism, 35–7

iron overload

beta thalassemias, 71

bone marrow assessment, 212

myelodysplastic disorders and, 233

transfusion therapy, 342

iron replacement, 41–2

thrombocytopenia, 159

iron stains, bone marrow specimens, 208, 210, 211–12

irradiated blood components, 241, 341, 349, 355

isochromosome 7q, 265

JAK2 inhibitors, primary myelofibrosis, 225

JAK2 mutations, 221, 222

jaundice

bleeding disorder, 132

folate/vitamin B12 deficiency, 55

HDN, 315, 316

juvenile myelomonocytic leukemia, 228–9
kallikrein/kinin system, 93–4, 97, 112
kaolin clotting time, 108
karyotypes, 217–18
  myelodysplastic disorders, 231, 232
  precursor lymphoid neoplasms, 255
Kasabach–Merritt syndrome, 162
kernicterus, 315
Ki-67, Burkitt lymphoma, 261
kidney
  erythropoietin, 16–17
  folate conservation, 52
  see also renal failure; uremia
kindlin 3 gene, 192
koilonychia, 29, 40
Kupffer cells, 3

laboratory assistants, bone marrow sampling, 202
lactate dehydrogenase, 78
lactation, folate requirement, 45
LAD-1, LAD-2, LAD-3 (leukocyte adhesion deficiency), 191–2
lamellar bone, 197
large cell lymphoma, see anaplastic large cell lymphoma; diffuse large B-cell lymphoma
large lymphocytes, 365, 379
lead poisoning, 68
lemon-tint icterus, 55
lenalidomide
  multiple myeloma, 296
  myelodysplastic disorders, 232–3
lepirudin, 136, 183
leukemias, 10, 15
  after chemotherapy, 275
  flow cytometry, 217
  stains for, 213
  see also specific types
leukemia reaction, septicemia, 240
leukocyte adhesion deficiency, 191–2
leukocyte alkaline phosphatase score, 89
leukocytes, see white blood cells
leukoerythroblastosis, 157
leukopheresis, 241
leukoreduction, RBC products, 333, 341–2
leukostasis, 239, 247
life spans
  erythrocytes, 3, 20
  neonates, 309
  neutrophils, 3
  plasma cells, 6–7
  platelets, reduction, 166–72
  see also half-life
light chain amyloidosis, 300–2
light chain assay (free light chain assay), 289–90
Lille score, primary myelofibrosis, 224
lipid products, erythrocyte membranes, transfusion-related acute lung injury, 329, 339
lipopolysaccharide, GVHD, 357
lipoproteins, 175–6
liver
  veno-occlusive disease, 349, 360, 361
  disease
    bleeding disorder, 138
    hematopoietic cell transplantation, 360–1
    hypersplenism, 160
  local anesthesia, bone marrow sampling, 202, 203
  long-term culture initiating cell assay, 11–12
  low density lipoprotein, 175–6
  low molecular weight heparin, 136, 178
  lung injury
    hematopoietic cell transplantation, 349, 361
    transfusion-related acute, 322, 329, 339
  lupus anticoagulants, 107–8, 181
  lymphadenopathy, 268–9
  lymph nodes
    anaplastic large cell lymphoma, 264
    angioimmunoblastic T-cell lymphoma, 265
    clinical features, 268–9
    germinal centers, 8
  Hodgkin lymphoma vs NHL, 269
  hyperplasia, 385
  mantle cell lymphoma, 259
  marginal zone lymphoma, 259–60
  lymphoblastic lymphoma, 282, 283
  lymphocyte predominant Hodgkin lymphoma, treatment, 275
lymphocytes, 4–5
  counts, pediatric, 309–10, 311
  development, 10
  large, 365, 379
  reactive, 365
  small, 363, 365, 380
  small cleaved, 386
see also B cells; NK cells; T cells
lymphocytosis, neonates, 309–10
lymphoid aggregates,
  immunohistochemistry, 214–16
lymphoid neoplasms
  with eosinophilia and PDGFRAx or FGR1 abnormalities, 227–8
WHO classification, 251–67
lymphomas
  classification, 251–67
  management, 268–86
lymphoplasmacytic lymphoma, 260, 303
  immunophenotyping, 253
lymphoproliferative diseases
  flow cytometry, 217
  neutropenia, 190
lyonization, X chromosome, 114–15
lysosomal trafficking regulatory protein, gene, 193
macrocytosis, neonates, 309
macroglossia, 301
macro-ovalocytes, 57, 376
macrophage colony-stimulating factor (M-CSF), 13
macrophages, 3, 7, 188
  siderotic granules, 212
macrothrombocytopenia, MYH9-related thrombocytopenia syndromes, 144, 158–9, 173
maintenance therapy
  acute lymphoblastic leukemia, 249
  acute myelogenous leukemia, 245
major basic protein, 4
major histocompatibility complex, 353
malabsorption
  iron deficiency anemia, 38–9
  vitamin B12 deficiency, 49
see also hereditary folate malabsorption
malaria hypothesis, 66
malignant disease, venous thrombosis risk, 182
malignant hypertension, 165
MALT lymphoma, 259
  antibacterial agents, 278–9
  genetics, 254
mantle cell lymphoma, 258–9, 282
  genetics, 254
  immunophenotyping, 253
mantle field, radiation therapy, 273
marginal zone lymphoma, 259–60
  immunophenotyping, 253
margination, 3
massive transfusion, 137–8
mast cells, 4, 7, 188
  degranulation, 227
  stains for, 213
mastocytosis, 222, 227
  systemic, 195, 227
maternal alloimmunization, 313–18
maternal autoantibodies, transplacental transfer, 318
mature B-cell lymphomas, 256–63
mature T-cell lymphomas, 263–6
May–Hegglin anomaly, 144, 145
Mayo Clinic score, primary myelofibrosis, 224
mean corpuscular hemoglobin (MCH), 25
  pediatric, 310
mean corpuscular hemoglobin concentration (MCHC), 25
  pediatric, 310
mean corpuscular volume (MCV), 25, 30, 32, 34
hemolytic anemias, 77
  pediatric, 310
mechanical hemolysis, 28
medical practitioners, bone marrow sampling, 201
Mediterranean macrothrombocytopenia, 144
medullary cavity, 197
megakaryocytes, 4, 9
  arrangement in marrow, 199
  bone marrow biopsy, 210
  bone marrow smears, 207–8
disorders, 158–9
  see also specific disorders
megakaryocytes, continued
myelodysplastic disorders, 231
osteoclasts vs, 198
megaloblastic anemias, 26, 377
DNA, 44
folate deficiency, 26, 44–61
neither B12 nor folate deficiency, 51
neutrophils, 56, 60, 377
peripheral blood smears, 45, 56–7
reticulocyte counts, 57
see also vitamin B12 deficiency
megaloblastosis, 56
bone marrow, 59
Melanesian elliptocytosis, 65
membranes
erythrocytes, 20–1
defects, 27–8, 63–5
lipid products, 329, 339
neonates, 309
platelets, 140
menstruation, anemia, 25, 39
mesoblastic period, hematopoiesis, 307
metabolism
erythrocytes, 21–3
iron, 35–7
metformin, vitamin B12 deficiency, 51
methemoglobin reduction pathway, 23
methionine, 49
methionine synthase, 48, 52
methotrexate, 358
methylcobalamin, 48
N5,N10-methylene-tetrahydrofolate reductase, 176
methylmalonic acid, levels, 57–9
methylmalonyl-CoA mutase, 48
methyl-tetrahydrofolate, 48–9, 52
mice, non-obese SCID, transplantation assays, 12
microangiopathic hemolytic anemias, 28, 372
fetus, 313
see also fragmentation hemolysis; thrombotic microangiopathy
microcytic anemias, 43
microcytosis, 367, 368, 369
thalassemia, 27
microenvironments, hematopoiesis, 12–13, 199
microscopy technique
bone marrow aspirates, 205–7
bone marrow biopsy, 208–9
microspherocytes, 64, 80, 82
microthrombocytopenia, 158
see also specific disorders
minimal residual disease, 245
flow cytometry, 217, 238
minor histocompatibility antigens, 353
mistransfusion, 337–8
mitoxantrone, acute myelogenous leukemia, 242
mixing test, 133
Modified Rai system, chronic lymphocytic leukemia, 279, 280
modifier genes, von Willebrand disease, 121
molecular biology, lymphomas, 254
molecular subtypes, acute myelogenous leukemia, 238, 239
monoclonal antibodies
acute lymphoblastic leukemia, 249
alemtuzumab, chronic lymphocytic leukemia, 280
indolent non-Hodgkin lymphomas, 276–7
radiolabeled, 278
monoclonal gammopathy of undetermined significance, 291,
293, 296–9
progression, risk factors, 297
monoclonal immunoglobulins, 134, 137, 287–90
see also plasma cells, disorders
monoclonal M-protein, 287–90, 298
monocytes, 3, 4, 7, 188, 365
counts, pediatric, 311
disorders, 195–6, 228–9, 382
graft-versus-host disease, 357
progenitors, 9
monocytosis, 195–6
mononuclear phagocytic system, 4
graft-versus-host disease, 357
iron release, 25
MOPP regimen, Hodgkin lymphoma, 274, 275
mortality, hematopoietic cell transplantation, 350, 362
M protein, 287–90, 298
M-spike, electrophoresis, 289, 294
mucocutaneous bleeding, von Willebrand disease, 121
multimers, von Willebrand factor, 121, 123, 163
multi-parametric ability, flow cytometers, 216
multiple myeloma, 290–6, 384
platelet defect, 134
smoldering, 291, 299–300
multipotent mesenchymal stromal cells, hematopoiesis, 13
muscle, bleeding, 115
mutations
acute myelogenous leukemia, 236
beta thalassemias, 70
hematopoietic stem cells, 15
hemoglobin, 19
hemophilia, 113–14
multiple myeloma, 293
red blood cell enzyme defects, 28
thrombocytopenia, 143–6
thrombopoietin receptor, 158
VWF gene, 121, 124–5
mycosis fungoides, 266, 279
myeloblasts, 9, 382
myelodysplastic disorders, 229–33
acute myelogenous leukemia and, 233, 245
secondary myelodysplastic syndrome/acute myeloid leukemia, 350
myelodysplastic/myeloproliferative neoplasms, 228–9
unclassifiable, 229
myelofibrosis, 2, 222, 223, 224–5
myeloid cells, 184–96
myeloid/erythroid ratio, 207, 210
myeloid neoplasms
with eosinophilia and PDGFRα or FGFRI abnormalities, 227–8
secondary myelodysplastic syndrome/acute myeloid leukemia, 350
therapy-related, 350
see also chronic myeloid leukemia
myeloid specific transcription factor C/EBPε, 193
myeloid system, 2–4
myeloma
POEMS syndrome, 302–3
see also multiple myeloma
myeloma kidney, 292
myeloperoxidase, deficiency, 194
myelophthisis (bone marrow infiltration), 26, 157
myelopoesis, 9
pediatric, 309–11
myeloproliferative neoplasms, 2, 220–7
see also myelodysplastic/myeloproliferative neoplasms
myelosuppression, see high-dose chemo-radiation therapy
MYH9-related thrombocytopenia syndromes, 144, 158–9, 173
myocardial infarction, venous thrombosis risk, 182
myoglobin, iron content, 35
myosin light chain kinase, 142
NADPH oxidase, 187, 192
nasal cavity, see extranodal NK/T-cell lymphoma, nasal type
natural killer cells, see extranodal NK/T-cell lymphoma, nasal type; NK cells
needles, bone marrow aspiration, 203
nelarabine, 249
neonatal alloimmune thrombocytopenia, 167, 317–18
neonatal autoimmune hemolytic anemia, 318
neonatal autoimmune neutropenia, 318
neonatal autoimmune thrombocytopenia, 318
neonatal purpura fulminans, 180
neonates
folate deficiency, 53
hematopoiesis, 309
hemoglobin, 308–9
hemolytic disease, 314–16, 336
hemophilia, 117–18
hemostatic system, 311–12
iron deficiency anemia, 39
lymphocytosis, 309–10
maternal alloimmunization, 313–18
white blood cell counts, 309–10
neutropenia, 189–90
HCT recovery, 349
HDN, 315
neonatal alloimmune, 317
neonatal autoimmune, 318
placental insufficiency, 313
neutrophilia, 189
neutrophils, 3, 7, 184–8, 364
counts, 188
pediatric, 309–10, 311
disorders, 188–94
hypersegmentation, 56, 57, 60
megaloblastic anemias, 56, 60, 377
nicotinamide adenine dinucleotide
phosphate oxidase, reduced, 187, 192
nilotinib, chronic myeloid leukemia, 226, 227
nitric oxide, 71–2
nitroblue tetrazolium, chronic
granulomatous disease, 193
nitrous oxide, 51
NK cells, 5
see also extranodal NK/T-cell
lymphoma, nasal type
nodal marginal zone lymphoma,
259–60
nodular lymphocyte predominant
Hodgkin lymphoma, 266–7, 272
nodular sclerosis classical Hodgkin
lymphoma, 267
non-enteropathic hemolytic uremic
syndrome, 164, 165–6
non-Hodgkin lymphomas
classification, 272
Hodgkin lymphoma vs, 268–72
treatment, 275–83
see also indolent non-Hodgkin
lymphomas
non-immune hemolytic anemias, 86–8
non-myeloablative conditioning, 243, 351
non-neuropathic amyloidosis, 300
non-obese SCID mice, transplantation
assays, 12
nonsecretory multiple myeloma, 293
nontropical sprue, 54
Normandy variant VWD, 125
normoblasts, 377
NOTCH1 mutation, acute lymphoblastic
leukemia, 247
nuclear-cytoplasmic dissociation, 44
nuclear factor kappa-B ligand, receptor
activator (RANKL), 198, 292
nucleated RBCs, fetus, 313
nutrient arteries, bone marrow, 199
nutrition
folate, 45–7, 53
iron, 37
pancytopenia, 158
parenteral, 360
vitamin B₁₂, 44–5
see also vegetarian diets
obesity
bone marrow sampling, 203
gastric bypass surgery, 38–9
venous thrombosis risk, 181
obligate carriers, hemophilia, 114
oligodendrocytes, 3
Ontak, 279
open canalicular systems, platelets,
140
oral contraceptives, see contraceptives
oral iron replacement, 41–2
orthochromatophilic normoblasts,
377
orthopedic surgery, venous thrombosis
risk, 182
osmotic fragility test, 64–5
osteoblasts, 197–8
osteoclasts, 198
osteocytes, 198
osteoid, 197
osteopetrosis, 352
osteoprotegerin, multiple myeloma,
292
osteosclerotic myeloma, 302–3
Ostertag type amyloidosis, 300
ovalocytes, 375
overload
circulatory, 328, 338–9
see also iron overload
oxidant stress, 28, 67
see also reactive oxygen species
oxygen transport, 19
oxyhemoglobin dissociation curve,
19–20
Index

P2Y₁₂ ADP receptor, disorder, 152
P₅₀ (oxygen affinity measure),
hemoglobin, 19
packed cell volume, see hematocrit
packed red cell transfusions, see
erthrocytes (RBC), transfusions
pain
  acute myelogenous leukemia, 240
  HCT, recovery, 348
  multiple myeloma, 291
painful crisis, sickle cell disease, 72
pancreatitis, TTP, 163
pancytopenia, 156–8
  transfusion-associated GVHD, 341
para-aortic field, radiation therapy, 273
paradoxical embolus, 182
paravalvular leak, 165
parenteral iron replacement, 42
parenteral nutrition, hematopoietic cell
transplantation, 360
paresthesias, vitamin B₁₂ deficiency, 55
parietal cells, antibodies, 59
Paris–Trousseau thrombocytopenia, 144
paroxysmal cold hemoglobinuria, 83–4
paroxysmal nocturnal hemoglobinuria, 28, 89–90
parvovirus infection, 14
passive alloimmune thrombocytopenia, 168
pathogen inactivated plasma products, 334
Pautrier microabscesses, 266
Pawn ball changes, 231
PDGFRα abnormalities, neoplasms with
eosinophilia, 227–8
Pelger–Hüet anomaly, 379
penia (suffix), 185
peri-orbital purpura, 301
periosteum, 197
peripheral blood smears, 31–2, 33, 34,
363
  elliptocytes, 66
hemolytic anemias, 79, 80
iron deficiency anemia, 40, 41
May–Hegglin anomaly, 145
megaloblastic anemias, 45, 56–7
peripheral T-cell lymphoma, not
otherwise specified, 263
Perl’s Prussian blue stain, 211
pernicious anemia, 26, 49
personnel
  bone marrow sampling, 201–2
  transfusion therapy, 330–1
petechiae, 154–5
HDN, 315
phagocytosis, 187
Philadelphia chromosome, see BCR-ABL
  fusion gene
philia (suffix), 185
phlebotomy, 221
phosphatidylinositol bisphosphate, 142
phosphatidylinositolglycan-linked
  membrane proteins, deficiency, 28
phosphatidyl serine, 101, 141
phospholipase A₂, 142
phospholipid-bound proenzymes, 93
phospholipids
  antibodies, 107–8
  platelets, 141, 152
physical examination, bleeding
disorders, 132–3
pica, 29, 40
pig-A gene, 89
placenta
  insufficiency, 55–6, 313
  transfer of maternal autoantibodies, 318
plasma
  fresh frozen, 128, 138, 333–4
  iron circulation, 36
  mixing test, 133
  platelet-rich, 147
  see also plasma products
plasmablastic lymphoma, 262–3
plasma cell leukemia, 304
plasma cells
  disorders, 287–306
  platelet defect, 134
  see also Waldenström’s
    macroglobulinemia
flow cytometry, 216
immunohistochemistry, 214
life span, 6–7
multiple myeloma, 384
plasma membranes, platelets, 140
plasmapheresis, HDN prevention, 315
plasma products, 333–4
  transfusion-related acute lung injury, 339
plasmin, 97
  disseminated intravascular coagulation, 138
plasminogen, 97
  see also dysplasminogenemia
plasminogen activator inhibitor, 92
plasminogen activator inhibitor-1, 97–8
deficiency, 110, 128–9
elevation, 181
plastic bags, blood banking, 319, 332
platelet clots, 175
platelet function analyzer-100, 147
platelet-rich plasma, 147
platelets, 4, 7, 92, 100–1, 140–53, 367
  activation mechanisms, 141–3
defects, 151–2
agglutination, 173
consumptive disorders, 161–6
  see also specific disorders
counts, 106, 133, 143, 146, 154
  normal with prolonged bleeding time, 109
  thresholds for transfusion, 334
defects, 109–10
  acquired, 132
formation, 9, 13
function, 141
  evaluation, 146–7
  inherited disorders, 146–53
  inherited disorders, 143–53
  laboratory tests, 133
  life span reduction, 166–72
neonates, 312
pediatrics, 311
plug formation, defective, 133–4, 138–9
regulation of number, 143
satellitism, 173
storage in vitro, 321
  bacterial contamination, 328, 340
transfusions of, 152, 334–5
  acute myelogenous leukemia, 241
  febrile reactions, 337
  HCT recovery, 349
  products for, 334–5
  refractoriness, 168, 335
von Willebrand factor assays, 123
pleomorphic variant, mantle cell lymphoma, 259
PML gene, translocations with RARα, 244
Pneumocystis jirovecii pneumonia, HCT, 361
POEMS syndrome, 302–3
poikilocytosis, 31, 368, 372, 374
polychromasia (polychromatophilia), 17–18, 372
polychromatophilic normoblasts, 377
polyclonal gammapathy, 287
polycthemia vera, 220–2
polymerase chain reaction
  alpha thalassemias, 70
  lymphomas, 254
polymerization, hemoglobin S, 71
polymorphonuclear neutrophils, see neutrophils
‘popcorn cells’, 266
portal hypertension, 138
posterior superior iliac crest, 203
postoperative thrombocytopenia, 163, 169
post-partum period, venous thrombosis risk, 182
post-procedure care, bone marrow biopsy, 205
post-remission therapy, acute myelogenous leukemia, 242–3
post-surgery TTP, 163
  see also postoperative thrombocytopenia
post-transfusion purpura, 168, 169, 340
potassium (K⁺), stored blood components, 321
prasugrel, 134, 177
precursor lymphoid neoplasms, 254–5
prednisone, graft-versus-host disease, 358
pregnancy
  folate deficiency, 53
  folate requirement, 45
  hyperhomocysteinemia, 55–6
  iron loss, 40
  Rh immunoglobulin therapy, 316, 336
  venous thrombosis risk, 182
  vitamin B₁₂ requirement, 44
  see also Rhesus system
prekallikrein, 93
  deficiency, 107
  screening tests and, 106
premedication, transfusion therapy, 337
prenatal testing, hemophilia, 118
pre-packed kit, bone marrow sampling, 202
preparative regimen, see high-dose chemo-radiation therapy
preservatives (for blood components), 332
preterm infants, physiologic anemia, 309
primary effusion lymphoma, 262–3
primary mediastinal large B-cell lymphoma, 262
primary myelofibrosis, 222, 224–5
prions, removal from blood products, 343
proaccelerin, see factor V
probes, FISH, lymphomas, 254
procoagulant states, inherited, 178–81
procoagulation activities, platelets, 141
disorders, 152
proenzymes, hemostasis, 92, 93
progenitor cells, 9, 10–12, 210
  harvesting, 347
  transplantation, see hematopoietic cell transplantation
proliferation centers, CLL/SLL, 256, 257
prolymphocytes, 256
prostheses, cardiovascular, 162
protease-activated receptors, 101
protein C, 92, 98
  deficiency, 179, 180
  pediatric, 312
protein kinase C, 142, 143
protein S, 98
  deficiency, 179, 180
  pediatric, 312
proteinuria, amyloidosis, 300–1
protein Z, 100
protein Z inhibitor, 100
prothrombin (factor II), 93, 95, 96
  deficiency, 127, 129
  neonates, 312
  screening tests and, 106, 107
  see also dysprothrombinemia
prothrombin 20210 (mutation), 179–80
prothrombinase assembly, 95
prothrombin complex concentrates, 128
  activated, 119–20
prothrombin time, 106, 107, 133
  activated partial thromboplastin time and, 108–9
  isolated prolonged, 108
  monitoring anticoagulation, 109
  neonates, 312
pseudo Pelger–Hüet abnormality, 231, 379
pseudo thrombocytopenia, 173
pulmonary edema, from transfusion therapy, 328
  see also transfusion-related acute lung injury
pulmonary embolism, thrombocytopenia, 163
pulmonary hypertension, thrombocytopenia, 163
pure red cell aplasia, 26
purpura, 104, 154–5
  peri-orbital, 301
  post-transfusion, 168, 169, 340
  see also specific diseases
purpura fulminans, 161
  neonatal, 180
pyrimidine 5’ nucleotidase deficiency, 68
pyruvate kinase deficiency, 21, 68
Quebec platelet disorder, 151
quinine
  drug-induced immune thrombocytopenic purpura, 168
  thrombotic thrombocytopenic purpura, 163
raccoon eyes, 301
radiation, see irradiated blood components
radiation therapy, 346
cytopenia, 14
  Hodgkin lymphoma, 272, 284
  fields, 273
radiation therapy, continued
indolent non-Hodgkin lymphomas, 277–8
total body radiation, 284, 348, 359
total nodal irradiation, 273
radiolabeled monoclonal antibodies, indolent non-Hodgkin lymphomas, 278
radioulnar synostosis, 158
Rai system, chronic lymphocytic leukemia, 279, 280
RANKL (receptor activator of NFκB ligand), 198, 292
Rapaport-Luebering pathway, 22
rapid-onset HIT, 169, 171
rare bleeding disorders, 127–8
rasburicase, 241
RBC storage lesion, 333
reactive lymphocytes, 365
reactive oxygen species
hyperhomocysteinemia, 177
neutrophils, 187
see also oxidant stress
reactive systemic amyloidosis, 300
rebound thrombocytosis, hemodilution, 159
receptor activator of NFκB ligand (RANKL), 198, 292
receptors, platelets, disorders, 151–2
recombinant factor VIIa (rVIIa), 119, 120, 153
reconstitution, immunologic, HCT, 355, 361
recovery, hematopoietic cell transplantation, 348–9, 359–61
recurrent or refractory aggressive NHL, hematopoietic cell transplantation, 285
red blood cells, see erythrocytes
red cell distribution width (RDW), 30, 32, 34
red clots, 175
reduced intensity conditioning, 243, 351
reduced nicotinamide adenine dinucleotide phosphate oxidase, 187, 192
Reed–Sternberg cells, 267, 387
refludan (lepirudin), 136, 183
refractory anemia with ring sideroblasts associated with marked thrombocytosis, 229
relapsed indolent NHL, hematopoietic cell transplantation, 284, 285
relative numbers of white cells, 185
release reaction, platelets, 141
remission acute myelogenous leukemia, 245
CLL/SLL, 276
induction therapy, see induction therapy
see also post-remission therapy
remodeling, bone, 198, 210
renal failure erythropoietin deficiency, 17, 25–6
multiple myeloma, 292–3
platelet defect, 134
transfusion reactions, 326
see also uremia
repeat heparin exposure, 172
resorption, bone, 198
respiratory distress syndrome (transfusion-related acute lung injury), 322, 329, 339
restless leg syndrome, 40
reticulin, 212
reticulin fibrosis, bone marrow, 210
reticulocytes, 3, 18, 80
counts, 30–1, 32
hemolytic anemias, 77
megaloblastic anemias, 57
reticuloendothelial system, see mononuclear phagocytic system
retinoic acid receptor alpha–PML gene, translocations, 244
retinopathy, sickle cell disease, 72
retroperitoneal hematoma, bone marrow sampling, 202
Rett syndrome, 53–4
Rhesus system chronic immune thrombocytopenia, 167
HDN, 314, 315
pretransfusion testing, 323
Rh immunoglobulin therapy, 316, 336
Richter’s syndrome, 256
ringed sideroblasts, 26–7, 212
ristocetin cofactor assay, 123, 126
ristocetin-induced platelet aggregation, 123, 148
rituximab
idiopathic TTP, 163
non-Hodgkin lymphomas
  aggressive, 281
  indolent, 276–7, 284
rolling, neutrophils, deficiency, 192
romiplostim, 15, 167
rouleaux, erythrocytes, 384
R-protein, 47
RUNX1-related mutations, 144, 152
Russell viper venom, see dilute Russell viper venom time
salvage therapy
  Hodgkin lymphoma, 274
  relapsed indolent NHL, 284, 285
sanctuary site relapse, acute lymphoblastic leukemia, 249
satellite bags, whole blood, 332
satellitism, platelets, 173
saturation, hemoglobin (P50), 19
Schilling test, 59
schistocytes, 28, 33, 63, 80, 163, 372
Scott syndrome, 142, 152
screening tests
  antibodies, transfusion therapy, 323–5
  bleeding disorders, 105–7, 133
  rare, 128
  hemophilia, 117
  von Willebrand disease, 123
secondary myelodysplastic syndrome/
  acute myeloid leukemia, 350
secretory vesicles, neutrophils, 188
sedation, bone marrow sampling, 202
selective serotonin reuptake inhibitors, 134
senile systemic amyloidosis, 300
sensory disorders, vitamin B12 deficiency, 55
septicemia
  consumptive thrombocytopenia, 162
  leukemoid reaction, 240
  neutropenia, 190
  from transfusion therapy, 340
sequestration (hypersplenism), 86–7, 132, 159–61
sequestration crisis, 72
serine protease inhibitors (SERPINs), 99–100
deficiency, 110, 180
serologic transfusion reactions, delayed, 338
serotonin release assay, heparin-induced thrombocytopenia, 172
serum, 5
serum amyloid A protein, 300
severe combined immunodeficiency, 352
severe congenital neutropenia, 190
sex difference, hemoglobin levels, 24
Sezary cells, 266
Sezary syndrome, 266
shelf life
  cryoprecipitate, 335
  RBC products, 333
Shigella, hemolytic uremic syndrome, 165
sialylated selectins, LAD-2, 192
siblings, hematopoietic cell transplantation, 354
sickle cell anemia, 27, 71
  fetal hemoglobin, 8
sickle cell disease, 71–3
sickle cells, 63, 373
sickle cell trait, 27, 71, 72
sideroblastic anemias, 26–7
sideroblasts, 211
  ringed, 26–7, 212
  siderotic granules, 211
skin
  folate/vitamin B12 deficiency, 55
  graft-versus-host disease, 358
  mycosis fungoides, 266, 279
  small cleaved lymphocytes, 386
  small lymphocytes, 363, 365, 380
  small lymphocytic lymphoma, 256
  immunophenotyping, 253
  see also chronic lymphocytic leukemia/
    small lymphoblastic lymphoma
smears
  bone marrow, 205–8
  see also peripheral blood smears
smoldering multiple myeloma, 291, 299–300
smudge cells, 380
somatic hypermutation, 8
Southeast Asian ovalocytosis, 65
specific granules, 187
deficiency, 193
spectrin, 20
hereditary elliptocytosis, 65
hereditary spherocytosis, 63, 64
spherocytes/spherocytosis, 27, 32, 33, 80, 82, 371
spicules, bone marrow aspirates, 205, 206
spinal cord, vitamin B\textsubscript{12} deficiency, 55, 60
spleen
marginal zone lymphoma, 259–60
sequestration crisis, 72
sickle cell disease, 72
see also hypersplenism; splenomegaly
splenectomy
for chronic immune thrombocytopenia, 166–7
differential cell counts, 186
hereditary spherocytosis, 65
primary myelofibrosis, 225
splenomegaly, 29
bleeding disorder, 132
cold agglutinin disease, 83
Hodgkin lymphoma vs NHL, 269
hypersplenism, 160
spontaneous HIT, 171–2
sporadic Burkitt lymphoma, 261
spur cells (acanthocytes), 33, 374
staff, see personnel
staging
lymphomas, 270–1, 280
multiple myeloma, 294
stains
bone marrow biopsy, 208, 212–15
see also immunohistochemistry; specific stains
Stanford V regimen, Hodgkin lymphoma, 274
‘starry sky’ pattern, Burkitt lymphoma, 261
stem cells, see hematopoietic stem cells
stem cell transplantation, see hematopoietic cell transplantation
sternum, bone marrow sampling, 201, 203
steroids, see corticosteroid therapy
storage
blood banking, 320–1
platelets, bacteria, 328, 340
white blood cells, 321–2
storage diseases, 353
storage lesion, erythrocytes, 333
storage pool deficiency, 142, 150–1
strokes
prevention, sickle cell disease, 73
venous thrombosis risk, 181
stroma, bone marrow, 13, 198–9
subclinical vitamin B\textsubscript{12} deficiency, management, 60
subendothelial tissue factor, see tissue factor
sucrose lysis test, 89
sulfasalazine, 54
supplementation, vitamin B\textsubscript{12} and folate, 46, 47
surface-bound proenzymes, 93
surface markers, see ‘CD’ (markers)
surgery
TTP after, 163
venous thrombosis risk, 182
survival, multiple myeloma, 295–6
sushi, tapeworms, 49
symptomatic carriers, hemophilia, 115
syngeneic hematopoietic cell transplantation, 345
systemic amyloidosis, 300
systemic lupus erythematosus, lupus anticoagulants, 107–8
systemic mastocytosis, 195, 227
T315I mutation, BCR-ABL fusion gene, 227
TACO, see circulatory overload
tacrolimus, GVHD prevention, 358
tapeworms, vitamin B\textsubscript{12} deficiency, 49
target cells, 34, 63, 368, 369
target joints, hemophilia, 115
T cell/histiocyte-rich large B-cell lymphoma, 262
T-cell lymphomas, 279
mature, 263–6
see also hepatosplenic T-cell lymphoma
T cells, 5, 8
  development, 10
  flow cytometry, 253
hematopoiesis, 13
hematopoietic cell transplantation, 354–9
tear-drop red cells (dacrocytes), 157, 376
TEL-AML1 translocation, 246
tenase assembly, 95, 113
terminal deoxynucleotidyl transferase, 255
terminal ileum, vitamin B₁₂ deficiency, 51
tetrahydrofolate (THF), 49, 52
thalassemias, 19, 27, 68–71, 369
  see also beta thalassemias
thalidomide, multiple myeloma, 296
thawed plasma, 333
therapy-related myeloid neoplasms, 350
thienopyridines, 134, 177
thin macrocytes, 57
3 + 7 protocol, acute myelogenous leukemia, 242, 243
thrombin, 92, 96, 97, 101
  bovine, 137
disseminated intravascular coagulation, 138
  in vitro formation, 321
thrombin clotting time, 106, 107
thrombin receptors, 101
thrombocytes, see platelets
thrombocytopenia, 14, 133–4, 154–73
  bone marrow smears, 207–8
  HDN, 315
  heparin-induced, see heparin-induced thrombocytopenia
  inherited disorders causing, 143–6
  neonatal alloimmune, 167, 317–18
  neonatal autoimmune, 318
  placental insufficiency, 313
  post-transfusion, 168, 169, 340
  see also thrombotic thrombocytopenic purpura
thrombocytopenia with absent radii, 145–6, 150, 158
thrombocytosis
  iron deficiency anemia, 40
  myelodysplastic disorders, 231
  refractory anemia with ring sideroblasts, 229
  see also essential thrombocythemia
thrombolytic therapy, 182
thrombomodulin, 92, 98
  hyperhomocysteinemia, 176, 177
thromboplastin, see tissue factor
thrombopoiesis, 9, 13
thrombopoietin, 9, 13, 143
  analogs, 15, 167
  thrombopoietin receptor, mutations, 158
thrombosis, 91, 174–83
  endothelial cells and, 92, 100
  heparin-induced thrombocytopenia, 136, 171
  thrombocytopenic disorders, 155
  thrombotic microangiopathy, 163–6
  see also microangiopathic hemolytic anemias
thrombotic thrombocytopenic purpura (TTP), 28, 163–6
  disorders mimicking, 165
  drug-induced immune thrombocytopenic purpura vs, 170
thromboxane, 134, 141–3
  impaired synthesis, 152
  thromboxane synthase, 142
thymus, B-cell lymphoma, 262
ticlopidine, 134
tingible body macrophages, Burkitt lymphoma, 261
tirofiban, 134, 178
tissue factor, 92, 94, 96, 97, 101
  prothrombin time, 106, 107, 108
tissue factor pathway inhibitor, 100
tissue plasminogen activator, 92–3, 97
tissue thromboplastin inhibition assay, 108
T lymphoblastic leukemia/lymphoma, 254–5
TNM classification, 270
tolerance induction regimens, 120
Toll-like receptors, graft-versus-host disease, 357
total body radiation, 284, 348, 359
total iron binding capacity (TIBC), 41
total nodal irradiation, Hodgkin lymphoma, 273
touch imprint, bone marrow, 211
tubular system, platelet, 140
tumor lysis syndrome, 241
tumor necrosis factor-α, GVHD, 357
two-chain urokinase plasminogen
activator, 97
typical-onset HIT, 169, 171
tyrosine kinase inhibitors
acute lymphoblastic leukemia, 250
chronic myeloid leukemia, 226–7
hypereosinophilic syndrome, 195

umbilical cord blood, 308, 344–5
matching, 354
unconjugated bilirubin, 79
unfractionated heparin (UFH), 136, 171, 178
unstable hemoglobins, 73–4
Upshaw–Schulman syndrome, 163
urea clot solubility assay, 128
uremia
erythrocytes, 33
platelet transfusions, 334
uric acid, excess prevention, 241
urine
hemosiderin, 80
protein electrophoresis, 289
urokinase type plasminogen activator, 97
Quebec platelet disorder, 151
urticarial transfusion reactions, 328, 337

vaccines, lymphomas, 278
valvular heart disease, 162–3
aortic stenosis, 132–3, 162–3
paravalvular leak, 165
variant Creutzfeldt–Jakob disease, risk from transfusion, 343
vascular endothelial growth factor (VEGF), POEMS syndrome, 302
vascular malformations, von Willebrand factor, 127
vascular occlusion, sickle cell disease, 72
vegetarian diets
iron deficiency anemia, 39
vitamin B₁₂, 45
replenishment, 60
VEGF, POEMS syndrome, 302
velocardiofacial syndrome, 145

translocations, 218
acute lymphoblastic leukemia, 246–7
acute myelogenous leukemia, 236
multiple myeloma, 293
PML gene with retinoic acid receptor alpha, 244
see also BCR-ABL fusion gene
transplacental transfer
maternal autoantibodies, 318
see also fetomaternal cell traffic
transplantation assays, hematopoiesis, 11–12
transplantation-associated alloimmune
thrombocytopenia, 168
transporter protein, folate, 52
transthyretin amyloidosis, 300
trisomies, 158
tropical sprue, 54
TTP, see thrombotic thrombocytopenic
purpura
veno-occlusive disease of the liver, 349, 360, 361
venous limb gangrene, warfarin, 162, 172
venous thrombosis, 178–83
viral infections
cytopenias, 14
differential cell counts, 186
hematopoietic cell transplantation, 355, 360
neutropenia, 190
from transfusion therapy, 320, 342
viscosity, blood, 5
vitamin B₁₂
deficiency, 26, 44–61
hyperhomocysteinemia, 176
dosages, 60
interactions with folate, 52
levels, 57
vitamin K, 93
antagonists, see warfarin
deficiency, 137
von Willebrand disease, 120–7, 142
Heyde’s syndrome and, 132–3
subtypes, 122, 124–6
see also acquired von Willebrand disease
von Willebrand factor, 92, 113, 120–1
acquired abnormalities, 126–7
assays, 123–4
concentrates, 126
neonates, 312
platelet adhesion, 141, 142
VWF antigen assay, 123
VWF gene, 121, 124–5
Waldenström’s macroglobulinemia, 260, 303–4
platelet defect, 134
warfarin
heparin-induced thrombocytopenia and, 172
mechanism, 93, 135, 183
monitoring, 109, 135
venous limb gangrene, 162, 172
warm antibody AIHA, 81–2, 371
warm autoantibodies, 28
WAS protein, 146
weight loss, lymphomas, 269
West Nile virus, risk from transfusion, 342
white blood cells, 7
antibodies, transfusion-related acute lung injury, 339
counts, 184, 185
neonates, 309–10
pediatric, 309–11
donation, 320
storage in vitro, 321–2
see also leukoreduction; specific types
WHO classification
acute lymphoblastic leukemia, 246, 247
acute myelogenous leukemia, 236, 237
lymphoid neoplasms, 251–67
myelodysplastic disorders, 230
whole blood (for transfusion), 332
Williams factor, see high molecular weight kininogen
Wilms’ tumor, von Willebrand factor, 126
Wiskott–Aldrich syndrome, 146, 150, 152, 158, 352
woven bone, 197
Wright–Giemsa stain, 363
X chromosome, lyonization, 114–15
X-linked disorders
hemophilia as, 113–14
thrombocytopenia, 146, 158
yolk sac, hematopoiesis, 8, 307
Ziehl–Neelsen stain, 213
Zollinger–Ellison syndrome, vitamin B₁₂
deficiency, 49
zymogens
hemostasis, 92, 93